United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo

United Therapeutics (NASDAQ:UTHR | UTHR Price Prediction) surged more than 12% in pre-market trading on March 30 after positive TETON-1 trial data triggered price target raises from two major Wall Street firms. The results validate a meaningful expansion of Tyvaso’s addressable market beyond pulmonary arterial hypertension into idiopathic pulmonary fibrosis, a condition with significant unmet need and limited treatment options.

The Analyst’s Case

BofA analyst Jason Gerberry raised his price target to $626 from $569, keeping a Neutral rating. Based on the combined TETON-1 and TETON-2 results, BofA sees a role for Tyvaso as both a monotherapy for patients unable to tolerate anti-fibrotics and as an adjunct therapy on top of anti-fibrotics. That dual-pathway argument is significant: it broadens the potential patient population rather than limiting Tyvaso to a single treatment slot in the IPF care pathway.

Wells Fargo raised its target to $575 from $486, also maintaining an Equal Weight rating. The firm characterized the TETON-1 data as “a nice win” and now assigns a 95% probability of success for an IPF approval. That confidence level is unusually high for a biotech catalyst and reflects the reinforcing effect of TETON-2’s earlier breakthrough results.

Why the Move Matters Now

United Therapeutics has spent years building a dominant PAH franchise. Tyvaso DPI generated $338.6 million in Q4 2025, up 24% year over year, making it the company’s primary growth engine. IPF represents a structurally larger opportunity, and a successful FDA submission would mark the first meaningful product-line extension beyond PAH in years.

CEO Martine Rothblatt framed the pipeline moment clearly: “The breakthrough results from our TETON-2 study in idiopathic pulmonary fibrosis could significantly broaden our therapeutic reach and accelerate our growth.” With TETON-1 now delivering positive data, that thesis is gaining hard evidence behind it.

The stock’s repricing reflects that market participants are already pricing in a high probability of approval. Shares closed at $588.36 on March 30, already above Wells Fargo’s revised $575 target and approaching BofA’s $626 ceiling. The year-to-date gain now stands at 20.75%, and the one-year return has reached 91.67%. The consensus analyst target sits at $605.75, with 9 Buy ratings and 4 Hold ratings across the coverage universe.

What Investors Should Watch Next

Both firms kept neutral-equivalent ratings even while raising targets substantially, which signals conviction in the pipeline story but caution on valuation after a sharp run. Full-year 2025 EPS came in at $27.86, beating estimates, while annual revenue reached $3,182.7 million. The fundamentals support the business; the question for long-term investors is whether the IPF opportunity is already priced in after a sharp run. The next hard catalyst is the ADVANCE OUTCOMES readout and targeted FDA submission in H2 2026 for ralinepag in PAH, which could provide the next leg of the thesis.